Rasburicase-Induced Methemoglobinemia

Moeed Ahmed 1, Thomas Sanchez 1, Selinaam Norgbe 1, Christopher R. Picking 1, Paul G. Millner 1

1. Internal Medicine, Creighton University School of Medicine, Omaha, USA

Corresponding author: Moeed Ahmed, moeedahmed22@gmail.com

Abstract

Methemoglobinemia occurs as iron in heme is oxidized to its ferric state, resulting in a decreased ability of hemoglobin to bind and release oxygen. Rasburicase is a recombinant urate-oxidase enzyme used in the prevention of tumor lysis syndrome. Methemoglobinemia can occur as a rare complication of treatment with rasburicase, primarily in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Methylene blue, an agent used for treating methemoglobinemia, should be avoided in patients with G6PD deficiency. In patients with G6PD deficiency, methylene blue is inadequately reduced to its active form, which then causes the methylene blue to further oxidize the hemoglobin to methemoglobin which can result in hemolysis.

Introduction

Rasburicase is a recombinant urate oxidase enzyme used in the prevention of tumor lysis syndrome in patients with malignancy. Tumor lysis syndrome (TLS) is a condition that occurs when a large number of cancer cells die within a short period, releasing their contents into the blood. When chemotherapy induces cellular death, nucleic acids are broken down, with one byproduct being uric acid. Uric acid can overwhelm the proximal tubular reabsorption capacity and cause acute kidney injury due to multiple mechanisms such as intrarenal crystallization, renal vasoconstriction, and inflammation [1,2]. The aforementioned prevention of tumor lysis syndrome is accomplished by rasburicase's ability to convert uric acid into allantoin, which is excreted by the kidneys [3]. Methemoglobinemia can occur as a rare complication of treatment with rasburicase, primarily in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This occurs when oxidizing agents, such as rasburicase, dapsone, nitrates, or methylene blue, converts iron from the ferrous (Fe2+) hemoglobin state to the ferric (Fe3+) methemoglobin state [4]. This causes a physiologic left shift in the oxygen dissociation curve leading to increased oxygen binding by red blood cells and decreased oxygen delivery to cells. G6PD-deficient individuals are more susceptible to methemoglobinemia from rasburicase.

Case Presentation

A 72-year-old man who was recently diagnosed with high-grade neuroendocrine carcinoma of prostate, small cell type, presented to the hospital for evaluation of shortness of breath and abdominal pain. Initially, he was suspected to have pulmonary embolism after a ventilation/perfusion (V/Q) scan showed intermediate probability for pulmonary embolism and lower extremity duplex confirmed an acute deep vein thrombosis (DVT) of the right femoral and popliteal veins. Initially, the patient did not require supplemental oxygen. Anticoagulation was initiated, resulting in gross hematuria due to his bladder mass and underlying prostate cancer.

Given the diagnosis of neuroendocrine carcinoma of the prostate, he was started on chemotherapy with carboplatin and etoposide. Subsequent blood workup revealed a creatinine of 4.07 mg/dl, potassium level of 5.2 mmol/L (normal: 3.7-5.1 mmol/L), phosphorus level of 5.9 mg/dl (normal: 2.5-4.9 mg/dl), and a uric acid level of 11.5 mg/dl (normal: 2.6-7.2 mg/dl). Given the concern for tumor lysis syndrome and renal dysfunction, he was started on rasburicase. Two to three days after starting rasburicase, his oxygen saturation was measured between 70% and 80% on room air, confirmed with a normal tracing on the plethysmograph. There was a notable discrepancy between transcutaneous oximetry and arterial blood gas oxygen saturation. He had no shortness of breath, and a chest radiograph was unremarkable. He was placed on four liter per minute oxygen via nasal cannula, with improvement in SpO2. Lungs were clear to auscultation. Hemoglobin was stable. The methemoglobin level was found to be elevated at 5.1% (normal: 0.0%-1.5%). There was high suspicion of rasburicase-induced methemoglobinemia; therefore, rasburicase was discontinued. Ascorbic acid and blood products were given, and the patient's oxygen saturation subsequently improved to over 90% on room air. A G6PD level with a corresponding red blood cell level of 2.98 m/μl (normal 4.3-5.9 m/μl) was ordered and subsequently came back low at 36 (normal range: 127-427 units/trillion RBCs).

Discussion

While the complication of rasburicase-induced methemoglobinemia is rare, occurring in fewer than 1% of
patients, this complication can be life-threatening [5]. Common presenting symptoms include, but are not limited to, dyspnea, dizziness, cyanosis, oxygen saturation between 70% and 85% with a normal partial pressure of oxygen on arterial blood gas, “chocolate”-colored blood, seizures, and arrhythmias [6]. The normal range of methemoglobin level in the blood is between 0% and 2%; while levels above 20% can cause symptoms, levels above 70% can cause death [7].

G6PD deficiency increases the risk for methemoglobinemia because this enzyme reduces glutathione which in the reduced state is a cellular buffer for oxidized molecules [8]. When hemoglobin is oxidized to methemoglobin by rasburicase, the cell’s capacity to reduce methemoglobin is overwhelmed, causing the toxic substance to build up in the body and present with symptoms [9]. Patients, especially in high-risk ethnic groups, should be tested for G6PD deficiency prior to the administration of rasburicase. Some of the factors that placed our patient at a higher risk for tumor lysis syndrome is that the patient had a solid tumor, which was responsive to the chemotherapy, as well as the fact that the patient had an existing renal dysfunction that may increase the risk of this patient progressing into tumor lysis syndrome [10]. There are fewer than 28 cases with a known rasburicase-induced methemoglobinemia in patients with a G6PD deficiency, and at least two cases of patients were found who died from complications associated with their methemoglobinemia [5,11-14]. Rasburicase should not be given to patients with a G6PD deficiency because hydrogen peroxide is produced when the rasburicase converts the uric acid to allantoin. Patients with a G6PD deficiency are not able to detoxify the hydrogen peroxide, which then starts to oxidize the hemoglobin to methemoglobin. Methylene blue, an agent used for treating methemoglobinemia, should be avoided in patients with G6PD deficiency considering that it is inadequately reduced to its active form, which can lead to hemolysis [15]. As rasburicase-induced methemoglobinemia mainly occurs in individuals with G6PD deficiency, empirical use of methylene blue should be avoided in these individuals. One of the concerns is that the G6PD level can take days to be resulted, which increases the importance of testing the patients earlier. Initial management involves discontinuation of the offending agent with subsequent options including the administration of ascorbic acid and blood administration.

Conclusions

Low oxygen saturation in a patient who is being given rasburicase should raise suspicion for methemoglobinemia, and these patients should be treated as being G6PD-deficient until the G6PD level is resulted. Methylene should be avoided in these patients to prevent hemolysis. Allopurinol may be considered as an alternative option in these patients.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We would like to acknowledge Dr. Saad Ur Rahman for his support in this article.

References

1. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med. 2008, 559:1811-21. 10.1056/NEJMoa0800885
2. Howard SC, Pui CH, Ribeiro RC: Tumor lysis syndrome. Renal Disease in Cancer Patients. Finkel KW, Howard SC (ed): Elsevier Science, Amsterdam, Netherlands; 2014. 59-64. 10.1016/B978-0-12-415948-8.00004-0
3. Ueng S: Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Baylor Univ Med Cent). 2005, 18:275-9. 10.1080/08998280.2005.11928082
4. Wright RO, Lewander WJ, Woolf AD: Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999, 34:646-56. 10.1016/s0196-0644(99)70167-8
5. Montgomery KW, Booth GS: A perfect storm: tumor lysis syndrome with rasburicase-induced methemoglobinemia in a G6PD deficient adult. J Clin Apher. 2017, 32:62-3. 10.1002/jca.21462
6. Ludlow JT, Wilkerson RG, Nappe TM: Methemoglobinemia. StatPearls Publishing, Treasure Island, FL; 2020.
7. Rehman HU: Methemoglobinemia. West J Med. 2001, 175:195-6. 10.1136/ewjm.175.3.193
8. Berg J, Tymoczko J, Stryer L: Glucose 6-phosphate dehydrogenase plays a key role in protection against reactive oxygen species. Biochemistry. 2002, 5:1-2.
9. Georgakoulí K, Fatouros IG, Dragadinos D, Papanikolaou K, Tsimeas P, Deli CK, Jamurtas AZ: Exercise in glucose 6-phosphate dehydrogenase deficiency: harmful or harmless? A narrative review. Oxid Med Cell Longev. 219, 2019:8060195. 10.1155/2019/8060195
10. Matuszkiewicz-Bowinska J, Malyszko J: Prevention and treatment of tumor lysis syndrome in the era of
onco-nephrology progress. Kidney and blood pressure research. Kidney Blood Press Res. 2020, 45:645–60. 10.1159/000509934

11. Sherwood GB, Paschal RD, Adamski J: Rasburicase–induced methemoglobinemia: case report, literature review, and proposed treatment algorithm. Clin Case Rep. 2016, 4:515-9. 10.1002/ccr3.495

12. Bucklin MH, Groth CM: Mortality following rasburicase–induced methemoglobinemia. Ann Pharmacother. 2013, 47:1353-8. 10.1177/1060028013501996

13. Cheah CY, Lew TE, Seymour JF, Burbury K: Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency. Acta Haematol. 2013, 130:254-9. 10.1159/000351048

14. Roberts DA, Freed JA: Rasburicase–induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem. Eur J Haematol. 2015, 94:83-5. 10.1111/ejh.12350

15. Richert M, Ali O, Stankiewicz J, Augenstein C, Trinidad LR: A case of rasburicase–induced methemoglobinemia due to glucose-6-phosphate dehydrogenase deficiency treated with hyperbaric oxygen therapy. Chest. 2019, 156:87-8. 10.1016/j.chest.2019.08.178